ceftriaxone sodium

Also found in: Dictionary, Thesaurus.
Related to ceftriaxone sodium: Cephalosporins, Rocephin

ceftriaxone sodium


Pharmacologic class: Third-generation cephalosporin

Therapeutic class: Anti-infective

Pregnancy risk category B

GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis, pancreatitis, Clostridium difficile-associated diarrhea


Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active against gram-negative and gram-positive bacteria, with expanded activity against gram-negative bacteria. Exhibits minimal immunosuppressant activity.


Powder for injection: 250 mg, 500 mg, 1 g, 2 g

Premixed containers: 1 g/50 ml, 2 g/50 ml

Indications and dosages

Infections of respiratory system, bones, joints, and skin; septicemia
Adults: 1 to 2 g/day I.M. or I.V. or in equally divided doses q 12 hours. Maximum daily dosage is 4 g.

Uncomplicated gonorrhea
Adults: 250 mg I.M. as a single dose

Surgical prophylaxis
Adults: 1 g I.V. as a single dose within 1 hour before start of surgical procedure

Adults: 1 g to 2 g I.V. q 12 hours for 10 to 14 days
Children: Initially, 100 mg/kg/day I.M. or I.V. (not to exceed 4 g). Then 100 mg/kg/day I.M. or I.V. once daily or in equally divided doses q 12 hours (not to exceed 4 g) for 7 to 14 days.

Otitis media
Children: 50 mg/kg I.M. as a single dose; maximum of 1 g/dose.

Skin and skin-structure infections
Children: 50 to 75 mg/kg/day I.V. or I.M. once or twice daily. Maximum dosage is 2 g daily.

Other serious infections
Children: 50 to 75 mg/kg/day I.V. or I.M. once or twice daily

Dosage adjustments

• Hepatic dysfunction with significant renal impairment

Off-label uses

• Disseminated gonorrhea

• Endocarditis

• Epididymitis

• Gonorrhea-associated meningitis

• Lyme disease

Neisseria meningitides carriers

• Pelvic inflammatory disease


• Neonates (28 days or younger)


Use cautiously in:

• hypersensitivity to cephalosporins or penicillins, allergies

• renal impairment, hepatic disease, gallbladder disease, phenylketonuria

• history of GI disease, diarrhea following antibiotic therapy

• pregnant or breastfeeding patients.


• Obtain specimens for culture and sensitivity testing as necessary before starting therapy.

Be aware that drug mustn't be given with or within 48 hours of calcium-containing I.V. solutions, including calcium-containing continuous infusions such as parenteral nutrition, because of risk of precipitation of ceftriaxone calcium salt (particularly in neonates).

• Know that drug for I.V. injection is compatible with sterile water, normal saline solution, dextrose 5% in water (D5W), half-normal saline solution, and D5W and normal saline solution.

• After reconstituting, dilute further to desired concentration for intermittent I.V. infusion. Infuse over 30 minutes.

• For I.M. use, reconstitute powder for injection with compatible solution by adding 0.9 ml of diluent to 250-mg vial, 1.8 ml to 500-mg vial, 3.6 ml to 1-g vial, or 7.2 ml to 2-g vial, to yield a concentration averaging 250 mg/ml.

• Divide high I.M. doses equally and administer in two separate sites. Inject deep into large muscle mass.

Adverse reactions

CNS: headache, confusion, hemiparesis, lethargy, paresthesia, syncope, seizures

CV: hypotension, palpitations, chest pain, vasodilation

EENT: hearing loss

GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis, pancreatitis, Clostridium difficile-associated diarrhea

GU: vaginal candidiasis

Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression

Hepatic: jaundice, hepatomegaly

Musculoskeletal: arthralgia

Respiratory: dyspnea

Skin: urticaria, maculopapular or erythematous rash

Other: chills, fever, superinfection, pain at I.M. injection site, anaphylaxis, serum sickness


Drug-drug. Aminoglycosides, loop diuretics: increased risk of nephrotoxicity

Calcium-containing solutions: possibly fatal reactions caused by ceftriaxone calcium precipitates

Probenecid: decreased excretion and increased blood level of ceftriaxone

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase: increased levels
Coombs' test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest): false-positive results

Hemoglobin, platelets, white blood cells: decreased values

Drug-herbs. Angelica, anise, arnica, asafetida, bogbean, boldo, celery, chamomile, clove, danshen, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng, horse chestnut, horseradish, licorice, meadowsweet, onion, papain, passionflower, poplar, prickly ash, quassia, red clover, turmeric, wild carrot, wild lettuce, willow: increased risk of bleeding.

Patient monitoring

Monitor for extreme confusion, tonic-clonic seizures, and mild hemiparesis when giving high doses.

• Monitor coagulation studies.

• Assess CBC and kidney and liver function test results.

• Monitor for signs and symptoms of superinfection and other serious adverse reactions.

• Be aware that cross-sensitivity to penicillins and cephalosporins may occur.

Patient teaching

• Instruct patient to report persistent diarrhea, bruising, or bleeding.

• Caution patient not to use herbs unless prescriber approves.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

ceftriaxone sodium

a parenteral third-generation cephalosporin antibiotic.
indications It is prescribed for infections of the lower respiratory tract, urinary tract, skin, abdomen, bones, and joints. It is also used to treat gonorrhea, septicemia, and meningitis and in surgical prophylaxis, particularly in coronary bypass operations. It has a comparatively long half-life and although its dosage must still be decreased with renal impairment, it is one of the few cephalosporins that is eliminated primarily by the liver.
contraindications It is contraindicated in patients who are hypersensitive to this product or to other cephalosporin antibiotics.
adverse effects Among reported adverse reactions are skin rash, diarrhea, eosinophilia, thrombocytosis, leukopenia, increased liver enzyme and blood urea nitrogen levels, and pain and tenderness at the site of injection.
Mentioned in ?
References in periodicals archive ?
Least square regression equation of ceftriaxone sodium in aqueous medium has shown that the [R.
Accuracy of the method was ascertained as mean % recovery between measured actual concentration and taken concentration for ceftriaxone sodium.
Ceftriaxone sodium sterile formulations were analysed by proposed method and by reported method [21], which involved the analysis of analyte with 0.
Ceftriaxone sodium was subjected to various stress conditions like acid, alkaline, hydrogen peroxide induced degradation, and thermal and photolytic condition.
Quin, "Simultaneous determination of the combined drugs ribavarin and ceftriaxone sodium in human urine by HPLC-DAD," International Journal of Science Innovations and Discoveries, vol.
An rphplc method for simultaneous estimation of Ceftriaxone sodium and sulbactam sodium in parenteral dosage form," International Journal of Pharmacy and Pharmaceutical Sciences, vol.
Ravi, "Validated ion pair HPLC method for simultaneous estimation of ceftriaxone sodium and tazobactum sodium in dosage form," International Journal of Pharma and Bio Sciences, vol.
Mruthyunjayaswamy, "Development and validation of a high-performance liquid chromatographic determination of ceftriaxone sodium and its application to drug quality control," Analytical Letters, vol.
Hedi, "HPLC method development and validation for the assay of ceftriaxone sodium injection," International Journal of Pharma Sciences, vol.
Singh, "Quantification of ceftriaxone sodium in pharmaceutical preparations by a new validated microbiological bioassay," Analytical Methods, vol.
Salgado, "Development and validation of a successful microbiological agar assay for determination of ceftriaxone sodium in powder for injectable solution," Pharmaceutics, vol.
Patel, "Development and validation of spectrophotometric method for determination of ceftriaxone sodium in pharmaceutical dosage forms," Der Pharma Chemica, vol.